Validation of the Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS) Tool for Use in a Physical Medicine Rehabilitation Clinic

NCT06329531 | Recruiting

• 2 other identifiers: 2022-0992NCI-2024-02555
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

To compare the results of the SOCS-OTS to another standardized screening measure that is currently being used by rehabilitation services at MD Anderson Cancer Center and to ensure that the SOCS-OTS correctly identifies those individuals needing OT services in cancer care.

Conditions

Cancer; Occupational Therapy

Outcome Measures

Primary Outcomes (1)

• Safety and adverse events (AEs)

  Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

  Through study completion; an average of 1 year.

Study Arms (1)

Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS)

You will be asked to complete three questionnaires and a short interview about yourself and how well you are able to complete your daily tasks. The SOCS-OTS, which is a 20-item questionnaire.

Other: Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS)

Interventions

Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS) OTHER

Given by Questionnaire

Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Cancer Participants

You may qualify if:

• Must be 18 years an older
• Currently medically followed in the PMR clinic (with or without acute disease)
• Must speak and read English. The AM-PAC is currently validated in adults only. Additionally, the assessment tools are in English without translation into other languages, therefore only clients who do speak and read English will be included. Pregnant participants are not excluded.

You may not qualify if:

• \. Potential participants with confusion and cognitive impairments that might hinder their ability to sign an informed consent form or participate in the study.

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead

Study Sites (1)

MD Anderson Cancer Center

Houston, Texas, 77030, United States

RECRUITING

Related Links

• MD Anderson Cancer Center

MeSH Terms

Conditions

Neoplasms

Study Officials

• Ekta Gupta, MD

  M.D. Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ekta Gupta, MD

CONTACT

(713) 745-2327; egupta@mdanderson.org

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 19, 2024
• First Posted: March 26, 2024
• Study Start: July 12, 2024
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: April 16, 2026

Record last verified: 2026-04

Locations

US (1)